Merck KGaA
Operates as a science and technology company providing life sciences products and services, healthcare pharmaceuticals across multiple therapeutic areas, and advanced materials for semiconductor manufacturing.
As of Aug 31, 2026
Summary
Merck KGaA is a German healthcare company traded on XETRA at €140.25, engaged in pharmaceuticals, chemicals, and life sciences. The technical setup currently favours the downside, though the stock has delivered a substantial 32.1% gain over the past year despite a 1.8% pullback in the last month. The €61.0 billion market cap underscores its position as a major player in the sector.
Price history
As of Aug 28, 2026
Performance
-0.89%
+1.67%
-1.82%
+7.27%
+16.69%
+32.10%
As of Aug 28, 2026
Technical indicators
- 52.3
- 0Bearish
- 50: 140.72 · 200: 124.11
- €135.30 / €140.35
Technical Bias
Bearish lean
Merck KGaA trades at €140.25 near its resistance level of €140.35. The technical indicators collectively lean bearish: MACD is flat at zero whilst RSI sits neutrally at 52.3, and moving averages offer no directional tilt. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 28, 2026
Fundamentals
- €61.0B
- 25.73
- €5.45
- 11.21%
- +3.4%
- €2.35B
- 0.81
- €98.72 – €148.80
- 1.57%
- Apr 27, 2026
- Nov 12, 2026 (72 days)
As of Aug 31, 2026
Upcoming catalysts
- Earnings report
As of Aug 31, 2026
Latest news
As of Aug 31, 2026
MonkeyTrade's Take on Merck KGaA
Short-term outlook
Merck KGaA's short-term setup leans mildly bearish: the MACD signal outweighs a neutral RSI and moving-average picture, and the stock is down 1.8% over the past month, sitting between its 50-day (€140.72) and 200-day (€124.11) averages. A break below €135.30 support would confirm the softer tone, while reclaiming €140.35 resistance would challenge it. No earnings catalyst is imminent, with the next report not due until November 2026.
Medium-term outlook
Merck KGaA's fundamentals look steady rather than exciting: modest 3.4% revenue growth, an 11.2% profit margin and a 1.6% dividend yield don't scream re-rating potential, especially with shares priced at 25.73 times earnings. Combined with a bearish technical lean, the medium-term picture skews cautious. A meaningful acceleration in revenue growth would be the key trigger to shift this view.
Key risks
- Increased competitive pressure in the industry is evident from moves like Sandoz's $322m Henlius deal targeting patent voids, which could squeeze pricing and market share for established players like Merck KGaA.
- Revenue growth of +3.4% year on year is relatively modest, leaving limited room to absorb any operational setbacks or pricing pressure.
- The stock trades at €140.25, well above its 52-week low of €98.72, so a meaningful pullback toward that lower range would represent a significant decline from current levels.
- A profit margin of +11.2% alongside a price-to-earnings ratio of 25.73 suggests the market is pricing in continued strong performance, which could leave the shares vulnerable if earnings growth fails to keep pace with that valuation.
About Merck KGaA
Merck KGaA is a German healthcare company operating in the drug manufacturing space, specifically within the specialty and generic pharmaceuticals segment. Listed on the XETRA exchange under the symbol MRK, the company holds a market capitalisation of €61.0 billion, reflecting its position as a substantial player within the broader healthcare sector.
Looking at the key figures, Merck KGaA trades on a price-to-earnings ratio of 25.73, giving investors a sense of how the market values its earnings relative to its share price. The company also offers a dividend yield of +1.6%, a detail worth noting for those tracking income-generating potential alongside sector positioning and overall market scale.
How to trade Merck KGaA
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.